Pfizer, Valneva say EMA validates Lyme vaccine marketing application

Reuters2026/08/14 05:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pfizer, Valneva Lyme vaccine candidate PF-07307405 marketing application validated by the EMA, triggering the start of the agency’s review.
Filing backed by Phase 3 VALOR data showing more than 70% efficacy in people aged 5 and older; no safety concerns identified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260813472879) on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pfizer, Valneva say EMA validates Lyme vaccine marketing application

You may also like

Crypto prices